公开(公告)号：US20240300974A1

公开(公告)日：2024-09-12

申请号：US18516014

申请日：2023-11-21

Applicant: Genentech, Inc.

Inventor： Snahel PATEL ,  Gregory HAMILTON ,  Guiling ZHAO ,  Huifen CHEN ,  Blake DANIELS ,  Craig STIVALA

IPC: C07D498/04 ,  A61P1/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/16 ,  A61P25/28 ,  C07D235/12 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D498/04 ,  A61P25/16 ,  A61P25/28 ,  C07D235/12 ,  C07D471/04 ,  C07D487/04 ,  A61P1/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00

Abstract: The invention provides novel compounds having the general formula I:




wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

公开(公告)号：US20240293829A1

公开(公告)日：2024-09-05

申请号：US18431838

申请日：2024-02-02

Applicant: Genentech, Inc.

Inventor： Nicholas RUMMEL ,  Patrick Daniel AHYOW

IPC: B04B7/00 ,  B33Y80/00 ,  C12M1/26

CPC classification number: B04B7/00 ,  B33Y80/00 ,  C12M33/10

Abstract: Provided herein are systems, devices and methods for harvesting biological cells with a centrifuge. A biological cell harvesting centrifuge apparatus may be provided with a rectangularly shaped base and 21 laterally spaced apart upright supports. Each upright support may extend vertically upward from the base and have a hollow core. Each upright support may be configured to slidably receive and support either one, two or four vertical edges of either one, two or four 15 mL micro bioreactor vessels. The 21 upright supports may be arranged in a 3×7 array such that they form a 2×6 array of receptacles configured to slidably receive and support 12 of the bioreactor vessels. The upright supports may be configured to support at least 80% of the vertical edges of the bioreactor vessels.

公开(公告)号：US12078638B2

公开(公告)日：2024-09-03

申请号：US17835418

申请日：2022-06-08

Applicant: Genentech, Inc.

Inventor： Priti Hegde ,  Mahrukh Huseni

IPC: C12Q1/6886 ,  A61K31/404 ,  A61K39/395 ,  A61K45/06 ,  A61P35/04 ,  C07K16/22 ,  C07K16/28 ,  G01N33/574 ,  A61K39/00

CPC classification number: G01N33/5748 ,  A61K31/404 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/04 ,  C07K16/22 ,  C07K16/2827 ,  C12Q1/6886 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., kidney cancer (e.g., renal cell carcinoma (RCC)), lung cancer (e.g., non-small cell lung cancer (NSCLC)), bladder cancer (e.g., urothelial bladder cancer (UBC)), liver cancer (e.g., hepatocellular carcinoma (HCC)), ovarian cancer, or breast cancer (e.g., triple-negative breast cancer (TNBC))). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a VEGF antagonist (e.g., an anti-VEGF antibody, (e.g., bevacizumab) or a VEGFR inhibitor (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib))) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)), or with an angiogenesis inhibitor (e.g., a VEGF antagonist (e.g., a VEGFR inhibitor, (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib)))).

公开(公告)号：US20240288430A1

公开(公告)日：2024-08-29

申请号：US18513107

申请日：2023-11-17

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Craig Anthony CUMMINGS ,  Yan LI ,  Sarah Margaret SHAGAN ,  Erica Beth SCHLEIFMAN ,  David SHAMES ,  David FABRIZIO ,  Daniel LIEBER ,  Geoffrey Alan OTTO ,  Mark KENNEDY ,  Travis CLARK ,  Doron LIPSON ,  Jie HE ,  Shan ZHONG

IPC: G01N33/574 ,  A61K39/00 ,  A61P35/00 ,  C07K14/735 ,  C07K16/28 ,  C12Q1/68 ,  C12Q1/6883 ,  G06F16/28 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70

CPC classification number: G01N33/574 ,  A61P35/00 ,  C07K14/70535 ,  C07K16/2827 ,  C07K16/2896 ,  C12Q1/68 ,  C12Q1/6883 ,  G01N33/57492 ,  G06F16/285 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/24 ,  C12Q2600/156 ,  G01N2333/70532 ,  G01N2800/52

Abstract: The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.

公开(公告)号：US12071425B2

公开(公告)日：2024-08-27

申请号：US17275606

申请日：2019-09-12

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle Braun ,  Cuong Q. Ly ,  Georgette Castanedo ,  Paul Gibbons ,  Wendy Lee ,  Joachim Rudolph ,  Nicole Alice Blaquiere ,  Jacob Bradley Schwarz ,  Ramsay Beveridge ,  Jean-Philippe Leclerc ,  Alexandre Lemire ,  Leo Fu

IPC: C07D401/14 ,  A61K45/06 ,  C07D401/04 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08

CPC classification number: C07D401/14 ,  A61K45/06 ,  C07D401/04 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08

Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US20240279327A1

公开(公告)日：2024-08-22

申请号：US18648653

申请日：2024-04-29

Applicant: Genentech, Inc.

Inventor： Germaine FUH ,  Chingwei V. LEE ,  Patrick KOENIG

IPC: C07K16/24 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07K16/46

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/247 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92

Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.

公开(公告)号：US20240277859A1

公开(公告)日：2024-08-22

申请号：US18682046

申请日：2022-08-22

Applicant: Genentech, Inc.

Inventor： Rachel Hendricks ,  Matthew Henry Hutchinson ,  Mark Frederick Fedesco ,  Bejamin Phu Tran

IPC: A61K47/68 ,  C07K1/107 ,  C07K1/18

CPC classification number: A61K47/68 ,  C07K1/1077 ,  C07K1/18

Abstract: The present invention relates to a method of developing purification processes for antibody drug conjugates using cation-exchange chromatography in flow-through mode leveraging the purification conditions of the antibody intermediate without a change to the critical quality attributes (CQA) of the ADC.

公开(公告)号：US20240261399A1

公开(公告)日：2024-08-08

申请号：US18364431

申请日：2023-08-02

Applicant: Genentech, Inc.

Inventor： Ariel LOPEZ-CHAVEZ ,  Daniel Antonius WATERKAMP

IPC: A61K39/395 ,  A61K9/00 ,  A61K31/365 ,  A61K33/243 ,  A61K39/00 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K31/365 ,  A61K33/243 ,  A61P35/00 ,  A61K2039/505

Abstract: The present disclosure provides methods for treating lung cancer (such as small cell lung cancer, e.g., extensive stage small cell lung cancer) in an individual. The methods comprise administering to the individual a PD-1 axis binding antagonist (such as an anti-PD-L1 antibody, e.g., atezolizumab), a platinum agent (e.g., cisplatin or carboplatin), and a topoisomerase II inhibitor (e.g., etoposide).

公开(公告)号：US20240254199A1

公开(公告)日：2024-08-01

申请号：US18489274

申请日：2023-10-18

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Amy Shen ,  Inn Huam Yuk ,  Gavin Christian Barnard ,  Shahram Misaghi ,  Simon Auslaender ,  Niels Bauer ,  Benedikt Oswald

IPC: C07K16/00 ,  C12N5/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  C12P21/00

CPC classification number: C07K16/00 ,  C12N5/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12P21/00 ,  C12N2310/20 ,  C12N2800/80

Abstract: The present disclosure relates to mammalian cells (e.g., Chinese Hamster Ovary (CHO) cells) that are modified to reduce or eliminate the expression of certain mammalian cell endogenous products (e.g., host cell proteins and virus-like particles), and methods of using such cells in the production of a recombinant product of interest, e.g., a recombinant protein, a recombinant viral particle, or a recombinant viral vector. These modifications were specifically chosen to generate engineered mammalian host cells with desired traits in several key areas, including improved cell culture performance (e.g., higher viability and product titers), improved product quality (e.g., more consistent and favorable glycosylation; more stable drug product), and decreased burden on purification for removing problematic or undesired endogenous host cell products (e.g., hydrolytic host cell proteins and virus-like particles) during biomanufacturing.

公开(公告)号：US20240247034A1

公开(公告)日：2024-07-25

申请号：US18497741

申请日：2023-10-30

Applicant: Genentech, Inc.

Inventor： Rami HANNOUSH ,  Harini KALUARACHCHI ,  Aaron NILE ,  Cameron NOLAND ,  Yingnan ZHANG ,  Lijuan ZHOU ,  Xinxin GAO

IPC: C07K14/415 ,  A61K9/00 ,  A61K9/50 ,  A61K38/00 ,  A61K38/16 ,  A61K47/34 ,  C07K14/00 ,  C07K14/47 ,  C07K14/81

CPC classification number: C07K14/415 ,  A61K9/0051 ,  A61K9/5031 ,  A61K38/00 ,  A61K38/168 ,  A61K47/34 ,  C07K14/001 ,  C07K14/4702 ,  C07K14/811 ,  C07K2319/70

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.